The chart below shows how SITM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SITM sees a +1.13% change in stock price 10 days leading up to the earnings, and a -0.33% change 10 days following the report. On the earnings day itself, the stock moves by -0.11%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Q4 Revenue Surge: Revenue for Q4 2024 grew 61% year over year, reaching $68.1 million, and for the full year, revenue increased by 41% to $202.7 million.
Gross Margin Improvement: Non-GAAP gross margins for Q4 were 58.8%, up 70 basis points sequentially, reflecting a favorable product mix.
Communications Market Sales Surge: Sales into the communications, enterprise, and data center market grew 156% year over year, contributing $24.8 million or 37% of total sales in Q4.
Earnings Per Share Increase: Non-GAAP net income for Q4 was $11.8 million, translating to earnings per share of $0.48, an increase from $0.40 per share in Q3.
Strong Cash Flow Position: Cash flow from operations for Q4 was $13.6 million, with a strong cash position of $419 million in cash, cash equivalents, and short-term investments.
Negative
Gross Margin Decline: Non GAAP gross margins decreased to 57% in Q1 2025, down from 58.8% in Q4 2024, attributed to revenue seasonality and increased depreciation costs from new product ramps.
Operating Expenses Management Challenges: Operating expenses for Q4 2024 were $32,500,000, with expectations of flat sequential growth in Q1 2025, indicating potential challenges in managing costs relative to revenue growth.
Accounts Receivable Concerns: Accounts receivable increased to $38,100,000 with days sales outstanding (DSOs) rising to 50 days, up three days from Q3, suggesting potential issues in cash flow management.
Inventory Increase Analysis: Inventory levels rose to $76,700,000 in Q4 2024, up from $71,900,000 in Q3, indicating possible overstocking or slower sales velocity.
Customer Concentration Risk: The largest customer accounted for 24% of total sales in Q4 2024, raising concerns about revenue concentration risk and dependency on a single client for future growth.
Earnings call transcript: Cytame Q4 2024 sees strong revenue growth
SITM.O
-0.1%